Society of Nuclear Medicine, Journal of Nuclear Medicine, 3(53), p. 363-370, 2012
DOI: 10.2967/jnumed.111.098319
Full text: Download
This first-in-human study was designed to evaluate the safety and dosimetry of the progesterone analog 21-18F-fluoro-16α,17α-[(R)-(1′-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione (18F-FFNP), as well the feasibility of imaging tumor progesterone receptors (PRs) by PET in breast cancer.